January 1, 2010
IBC’s Biopharmaceutical Development and Production Week covers today’s critical issues from all angles to provide you with a deeper understanding of the forces affecting your company and driving the bioprocessing industry. Customize your learning and networking experience with access to
700+ bioprocessing professionals under one roof
103 presenters to share strategies and lessons learned
45 exclusive case studies
five shared plenary sessions
two exhibit halls with >60 supplier companies.
Together, these five conferences deliver the latest technical and scientific approaches in upstream and downstream processing to accelerate development and optimize production. Benchmark your latest QbD/DoE efforts against those of industry leaders. Learn how new process validation guidelines will affect your manufacturing decisions. Hear how companies are integrating upstream and downstream processing and building a stronger connection with analytics at the process interface. Obtain practical tools and approaches to help make the best outsourcing decisions for your company’s needs. Examine proven approaches to ensure successful process and method transfers. Use proven approaches to overcome the upstream and downstream challenges in producing specific classes of proteins. Meet and network with >700 bioprocessing scientists and engineers.
Back By Popular Demand: Three strategic discussion groups will focus on new technologies for antibody purification, enabling technologies (What tools will take you to the next level?), and outsourcing of upstream bioprocess development. The fourth asks, “Can the biopharmaceutical industry make better progress by working as a community rather than as individual companies? What are the hurdles?”
Keynote Presentations
“Biotech 2010: Life Sciences Navigating the Sea of Change” by G. Steven Burrill, CEO of Burrill & Company
“Industrialization of MAb Production – Implications, Challenges and Opportunities” by Dana Anderson, senior director of process R&D at Oceanside operations and engineering for Genentech, Inc.
“Manufacturing Synagis: Life Cycle Management of a Life Saving Antibody” by Jeffrey Baker, senior director of manufacturing sciences at MedImmune
“The Future of Outsourcing: A CMO’s Perspective on Lessons Learned and Where We are Going” by John McGrath, business unit head of Lonza Biologics
“Global Regulatory Strategies for Validation and Transfer of Biotech Processes and Products” by Robert L. Garnick, president and CEO of Lone Mountain Biotechnology and Medical Devices, Inc.
“The Critical Elements of a Successful Regulatory Filing for Outsourcing Biopharmaceutical Manufacturing” by Terry Milby, director of regulatory CMC at Genentech, Inc.
“FDA and EMEA Feedback from a QbD Case Study: Upstream and Downstream Process Development Using a QbD Approach — Results from the CMC Biotech Working Group” by Victor A. Vinci, director of bioprocess operations in bioproduct R&D at Eli Lilly and Company, and Amit Banerjee, research fellow in global biologics at Pfizer Inc.
FIVE CONFERENCES, ONE LOCATION
Outsourcing Manufacturing of Biopharmaceuticals (1–2 March)
Process and Product Validation (1–2 March)
Technology Transfer for Biopharmaceuticals (1–2 March)
Antibody Development and Production (3–5 March)
Recombinant Protein and Complex Biologic Development and Production (3–5 March)
Conference Packages
IBC has designed conferences packages to fit all your needs. You can register for the best value 5-Day All Access Pass or for the individual conference of your choice. Early registration is encouraged to take advantage of pre-registration discounts. Group discounts are also available to groups of three or more. When registering, please mention priority code BDP2010FE.
Here’s what past attendees had to say:
“This conference had an atmosphere of open interaction from the questions being asked in the very first session.”
“The break-out discussion groups were engaging and interactive.”
“The quality of the presenters and the data were exceptional, and few events give attendees the opportunity to hear from so many well-known figures in the bioprocessing industry.”
You May Also Like
